TGTX

Business Context and Reporting Period

Company: Manhattan Pharmaceuticals, Inc. (Note: Metadata listed "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Stage: Development Stage Company. The company has generated no revenue from product sales to date. Operations focus on the development of Hedrin (head lice treatment) via a joint venture and a topical gel for psoriasis.

Key Financial Metrics

Note: The company reported a cumulative deficit of approximately $61.7 million from inception through September 30, 2009.

Material Changes vs. Prior Period

• Operating Expenses: Significant reduction in operating costs. Research and Development (R&D) expenses dropped 97% to $57,000 for the nine months ended September 30, 2009, compared to $1.86 million in the prior year period. General and Administrative (G&A) expenses decreased 47% to $1.37 million.
• Net Loss: Net loss for the nine-month period decreased 42% to $2.57 million from $4.40 million in the prior year, primarily driven by reduced R&D and G&A spending.
• Derivative Liability: A new derivative liability of $681,111 was recorded due to the reclassification of warrants issued to the Hedrin JV partner (Nordic) following new accounting standards (FASB). This resulted in a non-cash charge of $658,889 in the nine-month period.
• Liquidity: Cash and cash equivalents increased to $153,641 from $106,023 at year-end 2008, aided by financing activities.

Outlook, Risks, and Contingencies

• Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. They believe current resources are sufficient only through the end of 2009. Additional equity or debt financing is required to sustain operations into 2010.
• Joint Venture (Hedrin JV): The company holds a 50% interest in the Hedrin JV. The JV is responsible for all development costs of the Hedrin product. The company recognized $337,048 in equity losses from the JV for the nine-month period.
• Debt Obligations: The company has $1.725 million in principal of Secured 12% Notes payable, secured by substantially all company assets (excluding the Hedrin JV interest). Interest is compounded quarterly and payable at maturity.
• Legal Proceedings: An arbitration award of approximately $646,000 was rendered against the company by Swiss Pharma in 2008. This was settled in October 2009 (subsequent event) for $200,000 cash and a $250,000 promissory note.
• Product Pipeline: Development of Topical PTH (1-34) for psoriasis was terminated after Phase 2a results failed to show statistical significance. The company is exploring the vehicle gel used in the study as a potential OTC product.
• Acquisition: Entered a non-binding letter of intent to acquire Ariston Pharmaceuticals, Inc., contingent on regulatory milestones and funding.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured the additional financing required to operate beyond the end of 2009, as explicitly stated as a necessity in the filing.
• Debt Maturity: Confirm the status of the $1.725 million Secured 12% Notes and the ability to service interest or refinance upon maturity.
• Derivative Liability: Monitor the fair value of the derivative liability ($681,111) associated with the Nordic JV warrants, as fluctuations in stock price will directly impact net income.
• Swiss Pharma Settlement: Confirm the execution of the settlement terms (cash payment and note issuance) described in the subsequent events section.
• Ariston Merger: Assess the likelihood of the non-binding letter of intent with Ariston Pharmaceuticals becoming a binding agreement and the associated dilution from contingent share issuance.